Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …

Empaglifolzin, canagliflozin, and dapagliflozin are SGLT2 (sodium-glucose linked
transporter type 2) inhibitors for treatment of type 2 diabetes mellitus that also reduce blood …

The antidiabetic drug canagliflozin is reported to possess several cardioprotective effects.
However, no studies have investigated protective effects of canagliflozin in isoprenaline …

Glucose is the most abundant monosaccharide, and an essential source of energy for most
living cells. Glucose transport across the cell membrane is mediated by two types of …

Background Arterial stiffness is emerging as an independent risk factor for the development
of chronic kidney disease. The sodium glucose co-transporter 2 (SGLT2) inhibitors, which …

Li P, Bukhari SNA, Khan T, et al. Int J Nanomedicine. 2020; 15: 9115–9124. The Editor and
Publisher of International Journal of Nanomedicine wish to retract the published article …

Diabetes is a chronic metabolic disease, and its therapeutic goals focus on the effective
management of blood glucose and various complications. Drug combination therapy has …

Diabetes prevalence is constantly increasing and, nowadays, it affects more than 350 million
people worldwide. Therefore, the prevalence of diabetic nephropathy (DN) has also …

Na+-glucose cotransporter-2 (SGLT2) inhibitors are the new mainstay of treatment for
diabetes mellitus and cardiovascular diseases. Despite the remarkable benefits, the …

Diabetic nephropathy (DN) is a common complication of diabetes mellitus. While there has
been a great advance in our understanding of the pathogenesis of DN, no effective …